Kainate receptors belong to the family of glutamate receptors ion channels, which are responsible for the majority of rapid excitatory synaptic transmission in the central nervous system. The ...therapeutic potential of kainate receptors is still poorly understood, which is also due to the lack of potent and subunit-selective pharmacological tools. In search of selective ligands for the GluK3 kainate receptor subtype, a series of quinoxaline-2,3-dione analogues was synthesized and pharmacologically characterized at selected recombinant ionotropic glutamate receptors. Among them, compound
was found to be a competitive GluK3 antagonist with submicromolar affinity and unprecedented high binding selectivity, showing a 400-fold preference for GluK3 over other homomeric receptors GluK1, GluK2, GluK5 and GluA2. Furthermore, in functional assays performed for selected metabotropic glutamate receptor subtypes,
did not show agonist or antagonist activity. The molecular determinants underlying the observed affinity profile of
were analyzed using molecular docking and molecular dynamics simulations performed for individual GluK1 and GluK3 ligand-binding domains.
Kainate receptors belong to the family of ionotropic glutamate receptors and contribute to the majority of fast excitatory neurotransmission. Consequently, they also play a role in brain diseases. ...Therefore, understanding how these receptors can be modulated is of importance. Our study provides a crystal structure of the dimeric ligand‐binding domain of the kainate receptor GluK2 in complex with L‐glutamate and the small‐molecule positive allosteric modulator, BPAM344, in an active‐like conformation. The role of Thr535 and Gln786 in modulating GluK2 by BPAM344 was investigated using a calcium‐sensitive fluorescence‐based assay on transiently transfected cells expressing GluK2 and mutants hereof. This study may aid in the design of compounds targeting kainate receptors, expanding their potential as targets for the treatment of brain diseases.
X‐ray crystallography was used to determine an active‐like dimer of the ligand‐binding domain of GluK2, locating the positive allosteric modulator BPAM344 within the dimeric interface. Selected residues T535 and Q786 differing between GluK2 and GluA2 were investigated with calcium‐sensitive fluorescence‐based assays on transiently transfected cells. A three‐fold increase in BPAM344 potency occurred with the double mutant T535S‐Q786S in GluK2(Q).
Display omitted
•1.9 Å structure of the kainate receptor GluK1-LBD with kainate and BPAM538.•The positive allosteric modulator BPAM538 occupies two binding sites.•The binding mode is similar to class ...III modulators described for AMPA receptors.•BPAM538 prefers GluK1 over GluK2.
Kainate receptors play an important role in the central nervous system by mediating postsynaptic excitatory neurotransmission and modulating the release of the inhibitory neurotransmitter GABA through a presynaptic mechanism. To date, only three structures of the ligand-binding domain (LBD) of the kainate receptor subunit GluK1 in complex with positive allosteric modulators have been determined by X-ray crystallography, all belonging to class II modulators. Here, we report a high-resolution structure of GluK1-LBD in complex with kainate and BPAM538, which belongs to the full-spanning class III. One BPAM538 molecule binds at the GluK1 dimer interface, thereby occupying two allosteric binding sites simultaneously. BPAM538 stabilizes the active receptor conformation with only minor conformational changes being introduced to the receptor. Using a calcium-sensitive fluorescence-based assay, a 5-fold potentiation of the kainate response (100 μM) was observed in presence of 100 μM BPAM538 at GluK1(Q)b, whereas no potentiation was observed at GluK2(VCQ)a. Using electrophysiology recordings of outside-out patches excised from HEK293 cells, BPAM538 increased the peak response of GluK1(Q)b co-expressed with NETO2 to rapid application of 10 mM L-glutamate with 130 ± 20 %, and decreased desensitization determined as the steady-state/peak response ratio from 23 ± 2 % to 90 ± 4 %. Based on dose–response relationship experiments on GluK1(Q)b the EC50 of BPAM538 was estimated to be 57.5 ± 29.2 μM.
Mechanism and site of action of big dynorphin on ASIC1a Borg, Christian B.; Braun, Nina; Heusser, Stephanie A. ...
Proceedings of the National Academy of Sciences - PNAS,
03/2020, Letnik:
117, Številka:
13
Journal Article
Recenzirano
Odprti dostop
Acid-sensing ion channels (ASICs) are proton-gated cation channels that contribute to neurotransmission, as well as initiation of pain and neuronal death following ischemic stroke. As such, there is ...a great interest in understanding the in vivo regulation of ASICs, especially by endogenous neuropeptides that potently modulate ASICs. The most potent endogenous ASIC modulator known to date is the opioid neuropeptide big dynorphin (BigDyn). BigDyn is up-regulated in chronic pain and increases ASIC-mediated neuronal death during acidosis. Understanding the mechanism and site of action of BigDyn on ASICs could thus enable the rational design of compounds potentially useful in the treatment of pain and ischemic stroke. To this end, we employ a combination of electrophysiology, voltage-clamp fluorometry, synthetic BigDyn analogs, and noncanonical amino acid-mediated photocrosslinking. We demonstrate that BigDyn binding results in an ASIC1a closed resting conformation that is distinct from open and desensitized states induced by protons. Using alanine-substituted BigDyn analogs, we find that the BigDyn modulation of ASIC1a is primarily mediated through electrostatic interactions of basic amino acids in the BigDyn N terminus. Furthermore, neutralizing acidic amino acids in the ASIC1a extracellular domain reduces BigDyn effects, suggesting a binding site at the acidic pocket. This is confirmed by photocrosslinking using the noncanonical amino acid azidophenylalanine. Overall, our data define the mechanism of how BigDyn modulates ASIC1a, identify the acidic pocket as the binding site for BigDyn, and thus highlight this cavity as an important site for the development of ASIC-targeting therapeutics.
The kainate receptors GluK1‐3 (glutamate receptor ionotropic, kainate receptors 1–3) belong to the family of ionotropic glutamate receptors and are essential for fast excitatory neurotransmission in ...the brain, and are associated with neurological and psychiatric diseases. How these receptors can be modulated by small‐molecule agents is not well understood, especially for GluK3. We show that the positive allosteric modulator BPAM344 can be used to establish robust calcium‐sensitive fluorescence‐based assays to test agonists, antagonists, and positive allosteric modulators of GluK1‐3. The half‐maximal effective concentration (EC50) of BPAM344 for potentiating the response of 100 μm kainate was determined to be 26.3 μm for GluK1, 75.4 μm for GluK2, and 639 μm for GluK3. Domoate was found to be a potent agonist for GluK1 and GluK2, with an EC50 of 0.77 and 1.33 μm, respectively, upon co‐application of 150 μm BPAM344. At GluK3, domoate acts as a very weak agonist or antagonist with a half‐maximal inhibitory concentration (IC50) of 14.5 μm, in presence of 500 μm BPAM344 and 100 μm kainate for competition binding. Using H523A‐mutated GluK3, we determined the first dimeric structure of the ligand‐binding domain by X‐ray crystallography, allowing location of BPAM344, as well as zinc‐, sodium‐, and chloride‐ion binding sites at the dimer interface. Molecular dynamics simulations support the stability of the ion sites as well as the involvement of Asp761, Asp790, and Glu797 in the binding of zinc ions. Using electron microscopy, we show that, in presence of glutamate and BPAM344, full‐length GluK3 adopts a dimer‐of‐dimers arrangement.
How kainate receptors can be modulated by small‐molecule agents is not well understood. Establishment of calcium‐sensitive fluorescence‐based assays at GluK1‐3 allowed for high‐throughput screening for modulators and other ligands. Using X‐ray crystallography and molecular dynamics of an H523A mutant of the GluK3 ligand‐binding domain, here, we unraveled ion binding sites and dimer interface stabilization by the positive allosteric modulator BPAM344. Using electron microscopy, we show that BPAM344 and glutamate introduced an active‐like shape of full‐length GluK3. This figure was prepared with pymol (Version 2.0.3, Schrödinger, LLC).
The synthesis and biological evaluation on AMPA and kainate receptors of new examples of 3,4-dihydro-2H-1,2,4-thieno3,2-e-1,2,4-thiadiazine 1,1-dioxides is described. The introduction of a ...cyclopropyl chain instead of an ethyl chain at the 4-position of the thiadiazine ring was found to dramatically improve the potentiator activity on AMPA receptors, with compound 32 (BPAM395) expressing in vitro activity on AMPARs (EC2x = 0.24 μM) close to that of the reference 4-cyclopropyl-substituted benzothiadiazine dioxide 10 (BPAM344). Interestingly, the 4-allyl-substituted thienothiadiazine dioxide 27 (BPAM307) emerged as the most promising compound on kainate receptors being a more effective potentiator than the 4-cyclopropyl-substituted thienothiadiazine dioxide 32 and supporting the view that the 4-allyl substitution of the thiadiazine ring could be more favorable than the 4-cyclopropyl substitution to induce marked activity on kainate receptors versus AMPA receptors. The thieno-analogue 36 (BPAM279) of the clinically tested S18986 (11) was selected for in vivo evaluation in mice as a cognitive enhancer due to a safer profile than 32 after massive per os drug administration. Compound 36 was found to increase the cognition performance in mice at low doses (1 mg/kg) per os suggesting that the compound was well absorbed after oral administration and able to reach the central nervous system. Finally, compound 32 was selected for co-crystallization with the GluA2-LBD (L504Y,N775S) and glutamate to examine the binding mode of thienothiadiazine dioxides within the allosteric binding site of the AMPA receptor. At the allosteric site, this compound established similar interactions as the previously reported BTD-type AMPA receptor modulators.
Abstract
Kainate receptors are a class of ionotropic glutamate receptors that respond to the excitatory neurotransmitter glutamate in the central nervous system and play an important role in the ...development of neurodegenerative disorders and the regulation of synaptic function. In the current study, we investigated the structure‐ activity relationship of the series of quinoxaline‐2,3‐diones substituted at N1, 6, and 7 positions, as ligands of kainate homomeric receptors GluK1‐3 and GluK5. Pharmacological characterization showed that all derivatives obtained exhibited micromolar affinity at GluK3 receptors with
K
i
values in the range 0.1–4.4 μM range. The antagonistic properties of the selected analogues:
N
‐(7‐fluoro‐6‐iodo‐2,3‐dioxo‐3,4‐dihydroquinoxalin‐1(2
H
)‐yl)‐3‐sulfamoylbenzamide,
N
‐(7‐(1
H
‐imidazol‐1‐yl)‐6‐iodo‐2,3‐dioxo‐3,4‐dihydroquinoxalin‐1(2
H
)‐yl)‐3‐sulfamoylbenzamide and
N
‐(7‐(1
H
‐imidazol‐1‐yl)‐2,3‐dioxo‐6‐(phenylethynyl)‐3,4‐dihydroquinoxalin‐1(2
H
)‐yl)‐3‐sulfamoylbenzamide at GluK3 receptors, were confirmed by an intracellular calcium imaging assay. To correlate in vitro affinity data with structural features of the synthesized compounds and to understand the impact of the substituent in N1 position on ability to form additional protein‐ligand interactions, molecular modeling and docking studies were carried out. Experimental solubility studies using UV spectroscopy detection have shown that 7‐imidazolyl‐6‐iodo analogues with a sulfamoylbenzamide moiety at the N1 position are the best soluble compounds in the series, with molar solubility in TRISS buffer at pH 9 more than 3‐fold higher compared to NBQX, a known AMPA/kainate antagonist.
Kainate receptors are a class of ionotropic glutamate receptors that respond to the excitatory neurotransmitter glutamate in the central nervous system and play an important role in the development ...of neurodegenerative disorders and the regulation of synaptic function. In the current study, we investigated the structure- activity relationship of the series of quinoxaline-2,3-diones substituted at N1, 6, and 7 positions, as ligands of kainate homomeric receptors GluK1-3 and GluK5. Pharmacological characterization showed that all derivatives obtained exhibited micromolar affinity at GluK3 receptors with Ki values in the range 0.1-4.4 µM range. The antagonistic properties of the selected analogues: N-(7-fluoro-6-iodo-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl)-3-sulfamoylbenzamide, N-(7-(1H-imidazol-1-yl)-6-iodo-2,3-dioxo-3,4-dihydroquinoxalin-1(2H)-yl)-3-sulfamoylbenzamide and N-(7-(1H-imidazol-1-yl)-2,3-dioxo-6-(phenylethynyl)-3,4-dihydroquinoxalin-1(2H)-yl)-3-sulfamoylbenzamide at GluK3 receptors, were confirmed by an intracellular calcium imaging assay. To correlate in vitro affinity data with structural features of the synthesized compounds and to understand the impact of the substituent in N1 position on ability to form additional protein-ligand interactions, molecular modeling and docking studies were carried out. Experimental solubility studies using UV spectroscopy detection have shown that 7-imidazolyl-6-iodo analogues with a sulfamoylbenzamide moiety at the N1 position are the best soluble compounds in the series, with molar solubility in TRISS buffer at pH 9 more than 3-fold higher compared to NBQX, a known AMPA/kainate antagonist.
PDF
